Madrigal Pharmaceuticals MDGL
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Madrigal Pharmaceuticals (MDGL) Business Model and Operations Summary
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Key Insights
Madrigal Pharmaceuticals (MDGL) Core Market Data and Business Metrics
Latest Closing Price
$323.98Market Cap
$7.19 BillionPrice-Earnings Ratio
-14.79Total Outstanding Shares
22.08 Million SharesTotal Employees
528Dividend
No dividendIPO Date
February 6, 2007SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
200 Barr Harbor Drive, Suite 400, West Conshohocken, PA, 19428
Historical Stock Splits
If you bought 35 shares of MDGL before July 25, 2016, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| July 25, 2016 | 1-for-35 (Reverse Split) |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $5.10 Million |
| Net Cash Flow From Financing Activities | $735.06 Million |
| Net Cash Flow | $5.10 Million |
| Net Cash Flow From Financing Activities, Continuing | $735.06 Million |
| Net Cash Flow From Operating Activities | $-455.57 Million |
| Net Cash Flow From Investing Activities | $-274.39 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Diluted Earnings Per Share | $-21.90 |
| Net Income/Loss Attributable To Parent | $-465.89 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-465.89 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Net Income/Loss | $-465.89 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-465.89 Million |
| Comprehensive Income/Loss | $-465.89 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Assets | $1.04 Billion |
| Other Current Assets | $67.61 Million |
| Current Liabilities | $169.28 Million |
| Fixed Assets | $2.19 Million |
| Cash | $931.25 Million |
| Other Current Liabilities | $90.72 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||